

**Wanbury Limited**

**Regd. Office :** BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
+91-22-7196 3222  
Fax : +91-22-6794 2111/333  
CIN L51900MH1988PLC048455  
Email : info@wanbury.com  
Website : www.wanbury.com

November 18, 2025

BSE Limited PJ. Towers, Dalal Street Mumbai-400001 <b>Script Code:</b> 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400051 <b>Script Code:</b> WANBURY
-------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Sub.: Press release on Q2 & H1 FY26 Financial Results**

Please find attached herewith copy of press release on Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,  
**For Wanbury Ltd**



**Jitendra J. Gandhi**  
Company Secretary



## Wanbury Delivers Robust H1 FY26 Performance

### PAT jumps 216.6% YoY to Rs.28.7 Cr, driven by volume growth, cost efficiencies, improved Product yield and lower finance cost

**14<sup>th</sup> November, 2025, MUMBAI:** Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and half year ended 30<sup>th</sup> September, 2025.

#### Q2 & H1 FY26 Financial Highlights:

(Rs in Crore)

Particulars	Q2 FY26	Q2 FY25	Y-o-Y	Q1 FY26	Q-o-Q	H1 FY26	H1 FY25	Y-o-Y
Revenue from Operations	160.1	161.2	(0.7%)	163.2	(1.9%)	323.2	292.3	10.6%
EBITDA*	26.0	21.6	20.1%	24.8	4.8%	50.8	33.6	51.3%
EBITDA Margin (%)	16.2%	13.3%	292 bps	15.2%	105 bps	15.7%	11.4%	430 bps
PAT	15.2	8.0	89.3%	13.5	12.5%	28.7	9.1	216.6%
PAT Margin (%)	9.5%	4.9%	455 bps	8.2%	122 bps	8.9%	3.1%	578 bps

\*incl. other income

#### Financial Highlights:

##### For the quarter ended as on 30<sup>th</sup> September 2025

- Revenue from operations stood at Rs. 160.1 crore, compared to Rs.161.2 crore in Q2FY25
- EBITDA (including other income) for the quarter stood at Rs. 26.0 crore, as compared to Rs. 21.6 crore in Q2 FY25, registering a growth of 20.1% led by cost efficiencies & improved Product yield.
- EBITDA Margin stood at 16.2% compared to 13.3% in Q2FY25.
- PAT for the quarter stood at Rs. 15.2 crore, compared to Rs. 8.0 crore in Q2FY25, registering a robust growth of 89.3% led by cost efficiencies, improved Product yield & lower finance cost.
- PAT Margin stood at 9.5% for Q2FY26 compared to 4.9% for Q2 FY25

##### For half year ended as on 30<sup>th</sup> September 2025

- Revenue from operations for H1 FY26 stood at Rs. 323.2 crore, up from Rs. 292.3 crore in H1 FY25, reflecting a YoY growth of 10.6%, led by volume growth.
- EBITDA (including other income) for H1 FY26 stood at Rs.50.8 crore, compared to Rs. 33.6 crore in H1 FY25, registering a growth of 51.3% led by revenue growth, cost efficiencies and improved Product yield.
- EBITDA Margin stood at 15.7% compared to 11.4% in H1 FY25
- PAT for H1 FY26 stood at Rs. 28.7 crore, compared to Rs. 9.1 crore in H1 FY25, registering a growth of 216.6% led by volume growth, cost efficiencies, improved Product yield and lower finance cost
- PAT Margin stood at 8.9% for H1 FY26 compared to 3.1% for H1 FY25

*Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said,*

*“Q2 continues to be stronger with EBITDA achievement of ₹ 26.0 (16.2%) crore as compared to ₹21.6 (13.3%) crore in Q2 FY25, registering a growth of 20% over previous quarter, overall improvement of 292 bps of revenues. Further, achieved PAT of ₹ 15.2 crore as compared to ₹ 8.0 crore in Q2 FY25, registering a robust growth of approx. 90 % led by cost efficiencies, improved Product yield & lower finance cost.*

*This improvement was driven by several technical initiatives including enhanced product yields and higher solvent recoveries. Additionally, contributed by procurement efficiencies – such as improved negotiations through auction-based sourcing for large-volume raw materials and longer period suppliers’ contracts for KSM.*

*The Company’s Formulations business turned EBITDA positive supported by the successful launch of the new brand (C-red-advanced liposomal iron supplement), overall improved field productivity across Brands through targeted training of the sales force and various brand promotion activities.*

*The recent implementation of the SAP S/4HANA Private Cloud under the Rise with SAP initiative marks a significant milestone in our digital transformation journey. This will enable greater agility, operational transparency, and data-driven decision-making across the organization.*

*With our CAPEX plan on its way for introduction of new products, we remain committed to sustainable growth, increasing capacities, sustaining operational efficiencies and maintaining the highest standards of quality and compliance. Our efforts are aimed at strengthening Wanbury’s position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders.”*

### **About Wanbury Ltd.**

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.





For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

**Jitendra J. Gandhi**

**Company Secretary,**

**Wanbury Limited**

BSEL Techpark, B -Wing, 10th Floor,  
Sector 30-A, Opp. Vashi Railway Station,  
Vashi, Navi Mumbai - 400703,  
Maharashtra, India.

Tel: +91-22-6794 2222

Email: [jitendra.gandhi@wanbury.com](mailto:jitendra.gandhi@wanbury.com)

**Hanishi Shah / Smit Shah**

**Adfactors PR**

Oasis Complex, Kamala Mills Compound, City  
Hall, Pandurang Budhkar Marg,  
Lower Parel West,  
Mumbai – 400 021.

Tel: +91 9619059339 / +91 9870789596

Email: [hanishi.shah@adfactorspr.com](mailto:hanishi.shah@adfactorspr.com)

[smit.shah@adfactorspr.com](mailto:smit.shah@adfactorspr.com)

**Disclaimer:**

*This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*

